Immune checkpoint inhibitors and the development of granulomatous reactions - 07/02/19
, Paul Haun, MD a, Joseph English, MD b, Misha Rosenbach, MD aCet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Immune checkpoint inhibitors (ICPIs) have emerged as a frontline treatment for a growing list of malignancies. Disruption of the negative regulatory immune checkpoints by ICPIs has been associated with many immune-related adverse events. Granulomatous reactions, such as sarcoidosis-like reactions, granulomatous panniculitis, granuloma annulare, and granulomatous dermatitis, are uncommon but increasingly recognized immune-related adverse events seen in patients treated with ICPIs. The frequency and significance of these eruptions, including whether they portend responsiveness to treatment, remain unclear. Additionally, understanding the role of immune checkpoint blockade in these reactions may provide mechanistic insight into the relevant signaling pathways involved in sarcoidosis and other granulomatous disorders.
Le texte complet de cet article est disponible en PDF.Key words : checkpoint inhibitors, CTLA4, granuloma annulare, granulomatous, granulomatous dermatitis, granulomatous panniculitis, immune-related adverse events, PD-1, sarcoidosis
Abbreviations used : CTLA4, GA, GD, GR, ICPI, irAE, PD-1, PD-L1, SLR, Th17 cell
Plan
| Funding sources: None. |
|
| Conflicts of interest: Dr Rosenbach attended a single-day advisory board for Merck which included discussion about checkpoint inhibitor reactions. The other authors declared no conflicts of interest. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?